Review decision – September 2018
Decision to move the existing guidance to the static list
We would like to update you on the decision made regarding the review of the existing guidance on TA355; Edoxaban tosylate for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation.
No new evidence has emerged that is expected to substantially change the recommendations in TA355.
NICE’s Guidance Executive has decided to proceed with this proposal without consultation.
Consequently TA355 will move to the ‘static list’ of technology appraisals.
This page was last updated: